S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL

BACKGROUND: There are currently no approved medications for cognition in patients with schizophrenia. BI 425809, a glycine transporter 1 inhibitor, increases glycine in the synaptic cleft and may improve glutamatergic neurotransmission, synaptic neuroplasticity, and cognition. Pharmacotherapies targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hake, Sanjay, Huang, Songqiao, McDonald, Sean, Pollentier, Stephane, Podhorna, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Session I
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233981/
http://dx.doi.org/10.1093/schbul/sbaa031.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233981/
http://dx.doi.org/10.1093/schbul/sbaa031.106

Ejemplares similares